Roche's saves $476 million from Boehringer buy:
This article was originally published in Clinica
Roche says it has achieved 70% of potential synergies from its acquisition in mid-1997 of Boehringer Mannheim, with savings of around SwFr700 million ($476 million). The Swiss company also reported its net income for the full year - SwFr4.4 billion, a 3% increase on the previous year. Roche, which published sales figures in January (see Clinica No 842, p 8), anticipates another good result for 1999. The company also announced that chairman Fritz Gerber will be retiring. Franz Humer has been appointed CEO and as delegate to the board, and the company plans to elect Dr Humer as chairman on Mr Gerber's retirement.
You may also be interested in...
Oncology R&D isn’t waning, but investment in neurology and psychiatry drug development are paying off in new drug approvals. Rapid growth in CDER non-malignant hematology approvals reflects longer, broader trend toward orphan drugs.
We clean out your Martin Luther King Day inbox so you don't have to.
Political worries aside, industry is confidently executing on focused strategies as it welcomes a new decade, even if a lack of deal news at the J.P. Morgan Healthcare Conference didn't excite investors.